Highest level medical evidence proving the efficacy and safety of Fotona SMOOTH® modality for treatment of Stress Urinary Incontinence (SUI)

Published: Oct 18 2021

Key opinion leader Dr. Barry O’Reilly has presented the results of a multicentric randomized controlled trial of Fotona’s IncontiLase treatment at this year’s ICS Conference.

The results show that IncontiLase® performs significantly better than sham treatment in reducing the symptoms of SUI. The trial included 8 prominent European urogynecological investigators from the UK, Ireland, Switzerland, Greece and Slovenia, which were coordinated by Dr. Barry O’Reilly from Ireland.

Although it is not the first RCT for IncontiLase®, it is significant because it was the first multicentric trial and also included the widest array of objective and subjective measures, with up to 1 year follow up. The study provides the highest-level medical evidence of the efficacy and safety of the Fotona SMOOTH® laser modality for the treatment of stress urinary incontinence.

For more information see the abstract or watch Dr. O’Reilly’s lecture at the ICS conference.

Back

Find More Knowledge On:

Join Us on Social Networks

Download Fotona Mobile Application

All information published in this website is of general nature and only has an informative purpose. Under no circumstances can it replace any treatment or therapy prescribed by a physician or other healthcare professional. Any information on medical procedures and treatments in this website are intended for informative purposes only and do not provide the knowledge required for their application.

All Fotona medical lasers are CE marked and cleared for sale in the EU. For countries where specific national approvals or clearances are required (for example by the FDA in the United States), some of the products and/or applications may not have been cleared yet. Similarly, local patents may limit usage for certain technologies and applications. Please check with Fotona, your local Fotona distributor or your national regulatory body to find out whether a specific product or application is available for sale and use in your country.